Bio­gen, Sam­sung Bioepis look to carve up a block­buster Roche fran­chise with deep dis­count biosim­i­lar

Bio­gen and their biosim­i­lar part­ners at Sam­sung Bioepis are rolling out their copy­cat ver­sion of Roche’s an­ti-VEGF block­buster Lu­cen­tis to­day, 8 months af­ter it was ap­proved by the FDA. And they’re plan­ning to dive straight in­to a wet AMD mar­ket dom­i­nat­ed by Re­gen­eron’s Eylea with a hefty 40% dis­count off the brand­ed orig­i­nal.

The part­ners say they’ll of­fer By­ooviz for $1,130 per sin­gle-use vial, look­ing to an­gle in on a fran­chise that de­liv­ered $1.35 bil­lion to Roche sub­sidiary Genen­tech from US sales last year. Ex-US sales topped $2 bil­lion for No­var­tis, which shares com­mer­cial rights on the drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER